The invention is concerned with novel heteroarylacetamides of formula (I)
R—C(O)—N(R
e
)—R
c
—CH
2
—C(O)—N(R
a
)(R
b
) (I)
wherein R
a
to R
e
are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.